Get the Stockscreener App
2.40
0.00%
0.00
After Hours:
2.34
-0.06
-2.50%
Neuraxis Inc stock is traded at $2.40, with a volume of 16,173.
It is up +0.00% in the last 24 hours and down -24.76% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$2.40
Open:
$2.35
24h Volume:
16,173
Relative Volume:
0.85
Market Cap:
$16.75M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-2.9755
EPS:
-0.8066
Net Cash Flow:
-
1W Performance:
-3.23%
1M Performance:
-24.76%
6M Performance:
-11.11%
1Y Performance:
+13.74%
1-Day Range:
$2.31
$2.4915
1-Week Range:
$2.31
$3.34
52-Week Range:
$2.0001
$3.89
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
2.40 | 16.75M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neuraxis Inc Stock (NRXS) Latest News
FDA Approvals News Live Feed - StockTitan
Vagus Nerve Stimulators Market Growth in Future Scope 2024-2031 - openPR
NeurAxis (NASDAQ:NRXS) Stock Price Down 5.3% – Here’s What Happened - Defense World
NeurAxis Inc. Announces FDA 510(k) Clearance of Red for Testing and Evaluation of Patients with Chronic Constipation - Marketscreener.com
Connyct Launches on iOS: Build Your College Crew, Share Your Vibe, and Never Miss a Party - The Manila Times
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for - GlobeNewswire
NeurAxis Secures FDA Clearance for Revolutionary Chronic Constipation Testing Device - StockTitan
FDA Awards New Clearance to NeurAxis’ IB-Stim - MPO-mag
Rosalind Advisors, Inc. Acquires Significant Stake in Neuraxis I - GuruFocus.com
Neuraxis increases Series B Preferred Stock and extends dividend rights By Investing.com - Investing.com South Africa
Neuraxis increases Series B Preferred Stock and extends dividend rights - Investing.com
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage - MSN
Critical Review: BioSig Technologies (NASDAQ:BSGM) vs. NeurAxis (NASDAQ:NRXS) - Defense World
NeurAxis, Inc. (NASDAQ:NRXS) Q3 2024 Earnings Call Transcript - MSN
Neuraxis secures $5 million in preferred stock sale By Investing.com - Investing.com Nigeria
Neuraxis secures $5 million in preferred stock sale - Investing.com
Neuronetics Grants Inducement Awards to New Employees - MSN
NeurAxis Stock Surges After Strong Q3 Earnings And Expanded Coverage - Barchart
Neuraxis Inc. (NRXS) Quarterly 10-Q Report - Quartzy
NeurAxis reports 40% increase in revenues in Q3 2024 - Medical Buyer
NeurAxis Reports Strong Revenue Growth in Q3 2024 - TipRanks
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues - GlobeNewswire
NeurAxis Q3 Revenue Surges 40%, Expands Coverage to 35M Lives Amid FDA Milestone | NRXS Stock News - StockTitan
NeurAxis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market - Building Indiana
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024 - GlobeNewswire
NeurAxis (NRXS) Sets Q3 2024 Earnings Call for November 12 | Neuromodulation Leader | NRXS Stock News - StockTitan
IRIDEX (NASDAQ:IRIX) versus NeurAxis (NASDAQ:NRXS) Financial Survey - Defense World
NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024 - The Manila Times
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation - GlobeNewswire
Neuraxis adjusts equity agreement, secures additional funding - Investing.com India
Creatd (NASDAQ:VOCL) Stock Price Down 4.4% – Should You Sell? - Defense World
Technip Energies (OTCMKTS:THNPY) Trading Up 0.7% – Here’s What Happened - Defense World
Vestas Wind Systems A/S (OTCMKTS:VWSYF) Shares Up 1.2% – Here’s What Happened - Defense World
Zacks Initiates Coverage of NeurAxis With Neutral Recommendation - Yahoo Finance
The Zacks Analyst Blog Highlights Costco Wholesale, Alibaba, GE Aerospace, Applied Energetics and NeurAxis - Yahoo Finance
Top Analyst Reports for Costco Wholesale, Alibaba & GE Aerospace - Yahoo Finance
NeurAxis (NASDAQ:NRXS) Trading Up 6% - Defense World
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - GlobeNewswire
Neuraxis issues shares in equity financing By Investing.com - Investing.com Australia
Neuraxis issues shares in equity financing - Investing.com
Neuraxis Inc Stock (NRXS) Financials Data
There is no financial data for Neuraxis Inc (NRXS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Cap:
|
Volume (24h):